Visit biomodal at booth
The 2025 conference will explore the functional genomics of cancer, tumour heterogeneity, cellular metabolism, the tumour microenvironment, immunotherapy and other key themes such as:
Vice President, Global Marketing and Product Management
biomodal
Liquid biopsy (LBX) for profiling cell-free DNA (cfDNA) in blood is a promising method to enhance cancer management through early detection, monitoring and identification of residual disease. Early research focused on detecting actionable somatic mutations, but recent advancements have incorporated methylation. 5-methylcytosine (5mC) profiles of cancer are differential to non-cancer, and recent research has suggested that 5-hydroxymethylcytosine (5hmC) profiles in cfDNA can be a marker for early cancer.
We present a technology that sequences whole genome 6-base data (A, C, G, T, 5mC, and 5hmC) at single base resolution from cfDNA extracted from healthy volunteers and patients with colorectal cancer at stages I-IV. Our findings indicate that separate measurements of 5mC and 5hmC significantly enhance diagnostic accuracy for the detection of stage I CRC (AUC = 0.95) compared to traditional approaches that conflate these markers (modified C, AUC = 0.66). Notably, most regions with an increase in 5hmC in stage I CRC cfDNA also decreased in 5mC in stage IV CRC, suggesting that 5hmC can effectively track regions undergoing demethylation during tumour development. These results support the hypothesis that distinguishing between 5mC and 5hmC can improve the sensitivity of liquid biopsy tests for early cancer detection.
Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.
Unlock the power of the 6-base genome with duet evoC data, providing unprecedented insight, including A, C, G, T plus 5mC and 5hmC, in a single read. Learn more
“Our goal is to provide researchers and liquid biopsy clinical test developers with innovative tools that enable them to reveal previously undetectable biological changes,”
Formalin-fixed, paraffin-embedded (FFPE) specimens are commonly used for long-term storage in research and clinical settings, including immunohistochemistry, oncology, and genomics.
FFPE cancer samples are an incredibly important and clinically relevant information source for directly studying the causes and consequences of the disease. This technical note shows how duet evoC can identify DNA methylation markers from FFPE samples.
Liquid biopsy for profiling of cell free DNA (cfDNA) in blood holds huge promise to transform how we experience and manage. But can you get More information from limited DNA: simultaneous measurement of genetics, 5hmC and 5mC in cell-free DNA?
